安科生物：公司监事李城花辞职

Core Viewpoint - Anke Biotech announced the resignation of supervisor Li Chenghua due to personal reasons, effective immediately, and she will not hold any other positions within the company [2]. Financial Performance - For the first half of 2025, Anke Biotech's revenue composition is as follows: Gene engineering drugs account for 73.51%, other businesses account for 16.77%, and external patches account for 9.72% [2].